Invesco’s Monopar Therapeutics MNPR Stock Holding History

Invesco’s Portfolio MNPR Stock Details MNPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,355	Closed	-$219K	–	3795
2025 Q4	$219K	Buy	+3,355	New	+$274K	﹤0.01%	3494

Other funds holding MNPR

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco's MNPR Position: Q1 2026 in Review

Invesco sold out of Monopar Therapeutics (MNPR) in Q1 2026, closing a stake of 3,355 shares — an estimated $219K sold.

Invesco first reported a position in MNPR in Q4 2025 and held it in 1 quarter. The position peaked at $219K in Q4 2025. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

Invesco reported no remaining Monopar Therapeutics position as of Q1 2026 after selling out during the quarter.
Invesco sold 3,355 Monopar Therapeutics shares in Q1 2026, an estimated $219K.
Invesco first reported a position in Monopar Therapeutics in Q4 2025 and held it in 1 quarter.
Invesco's Monopar Therapeutics position peaked at $219K in Q4 2025.
82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.